GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Additional Paid-In Capital

SNY (Sanofi) Additional Paid-In Capital : $341 Mil(As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Sanofi Additional Paid-In Capital?


Sanofi's quarterly additional paid-in capital increased from Jun. 2023 ($152 Mil) to Dec. 2023 ($341 Mil) but then stayed the same from Dec. 2023 ($341 Mil) to Jun. 2024 ($341 Mil).

Sanofi's annual additional paid-in capital declined from Dec. 2021 ($601 Mil) to Dec. 2022 ($132 Mil) but then increased from Dec. 2022 ($132 Mil) to Dec. 2023 ($341 Mil).

Sanofi Additional Paid-In Capital Historical Data

The historical data trend for Sanofi's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Additional Paid-In Capital Chart

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 163.33 647.20 601.13 132.42 341.33

Sanofi Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 586.68 132.42 151.68 341.33 341.23

Sanofi Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Sanofi Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Sanofi's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Additional Paid-In Capital
Comparable Companies
XPAR:VIRP LLY OCSE:NOVO B JNJ ABBV MRK XSWX:ROG XSWX:NOVN LSE:AZN AMGN PFE BMY GILD LSE:GSK TSE:4519 TSE:4568 SHSE:600276 TSE:4578 BIIB XTER:BAYN
Traded in Other Exchanges
SNYNF:USA SNY:Mexico 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria
Address
46, avenue de la Great Army, Paris, FRA, 75017
Website
https://www.sanofi.com
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.